CLINICAL_TRIALS
research
· 2025-04-04
Clinical Trial Update: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients [Phase 2]
Summary
Phase 2 trial update indicates a study of copanlisib in combination with rituximab for marginal zone lymphoma is currently active but not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Christian Buske | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING